![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 52, 37379-37384, December 24, 1999
From the Department of Pharmacology, Wayne State University and the Program in Molecular Biology and Genetics, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201
| |
ABSTRACT |
|---|
|
|
|---|
The Ras-GRF1 exchange factor is strongly
implicated in the control of neuronal Ras. The activity of Ras-GRF1 is
regulated by increases in intracellular calcium and the release of
G The Ras GTPases are known to play central roles in pathways of
cellular growth and differentiation (1). Their function in terminally
differentiated cells such as neurons is less clear, but they have been
suggested to participate in learning and memory (2). As timed,
molecular switches they cycle between active (GTP-bound) and inactive
(GDP-bound) conformations under the control of guanine nucleotide
exchange factors (GEFs)1 and
GTPase-activating proteins (3). The balance of the effective GEF and
GTPase-activating protein activities determines the activation state of
Ras proteins. Regulation of the activity or subcellular localization of
a specific GEF is now recognized as the major control for Ras activity
in many instances (4).
The Ras-GRF1 exchange factor (5), which was also previously known as
CDC25Mm (6, 7), is implicated in neurotransmission.
Ras-GRF1 is highly expressed in neurons of the central nervous system
(8-10) and is present in postsynaptic densities (11). Mice that lack the expression of Ras-GRF1 have defects in the consolidation of memory
(12) and in postnatal growth (13). The latter may be due to a decrease
in circulating insulin-like growth factor-1 levels that is secondary to
changes in the hypothalamus (13).
In contrast to the Sos exchange factors, which couple tyrosine
kinase-derived signals to the activation of Ras (14, 15), Ras-GRF1
links heterotrimeric G-proteins (16-19) and calcium signals (20) to
Ras. Further, regulation through Sos occurs by translocation of the GEF
from the cytosol to its substrate, Ras, at the plasma membrane (21),
whereas Ras-GRF1 has not been found to undergo obvious subcellular
redistribution (22). Muscarinic acetylcholine receptors, for example,
stimulate an increase in the phosphorylation state of Ras-GRF1 that is
closely associated with an increase in its exchange activity toward Ras
(18). In this study, serine 916 of Ras-GRF1 is shown to be
phosphorylated in response to the activation of co-expressed muscarinic
receptors. This residue is an in vivo and in
vitro substrate for PKA, but another kinase is likely to be
responsible for its phosphorylation in response to carbachol
stimulation. Phosphorylation of serine 916 is necessary but not
sufficient for maximal activation of Ras-GRF1.
Plasmids and Truncation Mutants--
Constructs in the pKH3
vector (23) that encode full-length Ras-GRF1 and the N-terminal half
(residues 1-631, called Site-directed Mutagenesis--
The pKH3 vector was cut with
PstI, reacted with T4 DNA polymerase, and then ligated to
destroy the PstI site in the multiple cloning cassette (this
vector is called
To make full-length Ras-GRF1 with the S916A mutation, the
BamHI/EcoRI and EcoRI/EcoRI
fragments that encode the complete wild-type sequence (6) were
subcloned into Cell Culture, Transfection, and Metabolic Labeling--
Culture
and transfection of NIH-3T3/hm1 and NIH-3T3/GRF1 fibroblasts and COS-7
cells using calcium phosphate co-precipitation has been described
previously (23). Cultures were labeled with 1 mCi/100-mm dish
[32P]orthophosphate, lysed, and the
hemagglutinin-13-Ras-GRF1 was immunoprecipitated as
described (19).
Cyanogen Bromide (CNBr) Digestion--
Immunoprecipitated,
labeled Ras-GRF1 was boiled in Laemmli sample buffer (25), and a small
portion was taken for direct SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). The majority of the sample was removed to a new tube and
precipitated with 10 volumes of acetone at In Vitro Kinase Assays--
Glutathione S-transferase
(GST)-GRF1(900-983) wild-type and GST-GRF1(900-983)916A were prepared
according to standard protocols (26) and stored at MonoQ Chromatography--
Chromatography was performed at
4 °C with 0.5 ml/min flow rate. The column was first cleaned with
2.5 ml of 4 M guanidine-HCl in 25 mM Tris, pH
9.0, and then 5.0 ml of 0.5 M NaCl in 25 mM Tris, pH 7.4. The column was then equilibrated with 0.5 mM
dithiothreitol in 25 mM Tris, pH 7.4, to give a stable
baseline (UV at 280 nm) and the sample injected. A linear gradient to
0.5 M NaCl in equilibration buffer was developed from 3 to
32 min with collection of 1 min fractions.
Muscarinic Receptors Stimulate Phosphorylation of Ras-GRF1 at
Serine 916--
Ras-GRF1 can be activated by carbachol, a muscarinic
agonist, in transiently transfected NIH-3T3 fibroblasts that
constitutively express hm1, or when co-expressed with hm1 or hm2 in
COS-7 cells (18). The increase in exchange activity that can be induced in fibroblasts is closely associated with an increase in the
phosphorylation state of Ras-GRF1 (18). In order to map the regulated
phosphorylation sites on Ras-GRF1, epitope-tagged Ras-GRF1 was
transiently co-expressed with hm1 in COS-7 cells that were then labeled
with 32P-orthophosphate and stimulated with carbachol. The
immunoprecipitated Ras-GRF1 was then digested with CNBr (Fig.
2A). Carbachol stimulation induced the appearance of a fragment that has a mobility similar to
that of the aprotinin molecular mass marker (6.5 kDa). Inspection of
the sequence of Ras-GRF1 predicted that CNBr could produce a 6.5-kDa
fragment representing residues 334-386 in the N-terminal half of the
protein and a 7.2-kDa fragment representing residues 916-976 in the
C-terminal half of the protein. Deletion mutants of Ras-GRF1 that
encompass the N-terminal half (residues 1-631, called
A further deletion mutant was prepared that encompasses residues
900-983 to confirm the conclusion that the region 916-976 of Ras-GRF1
contains a regulated phosphorylation site. In both COS-7 cells, when
co-transfected with hm1 (not shown), and in NIH-3T3/hm1 fibroblasts
(Fig. 3A), carbachol induced a
clear increase in the phosphorylation state of this region of Ras-GRF1.
Phosphoamino acid analysis confirmed that phosphoserine was
incorporated into this piece (data not shown). Replacement of each of
the Serine residues with alanine demonstrated the phosphorylation in
this region occurred at residue 916. Replacement of residue 916 with threonine generated a fragment that was weakly phosphorylated in
response to carbachol stimulation (Fig. 3B). Phosphoamino
acid analysis demonstrated that phosphothreonine was produced in this mutant (not shown), further confirming 916 as a true in vivo
phosphorylation site.
Phosphorylation at Serine 916 Is Necessary for Full Activation
of Ras-GRF1 by Muscarinic Receptors--
To establish whether
phosphorylation at serine 916 was required for
carbachol-dependent activation of Ras-GRF1, the S916A mutation
was inserted into the full-length protein. Exchange factor assays
performed on the mutant and wild-type Ras-GRF1 proteins showed that
although there was no apparent difference in the basal GEF activity of
the two constructs, the S916A mutation prevented full activation by
carbachol in NIH-3T3/hm1 fibroblasts (Fig. 4). These results indicate that
phosphorylation at serine 916 is necessary for maximal activation of
Ras-GRF1 by muscarinic receptors.
Serine 916 of Ras-GRF1 Is a Substrate for PKA--
Review of the
sequence around serine 916 revealed a consensus site for
phosphorylation by PKA (28).
To confirm the characteristics of the kinase activity in the intact
cell, Ras-GRF1(900-983) was transiently expressed in NIH-3T3/hm1 fibroblasts. Treatment of the cells with the cell-permeable and hydrolysis-resistant PKA inhibitor Rp-cAMP-S (34) did not prevent carbachol-stimulated phosphorylation (Fig.
6A). Forskolin, an activator
of PKA, in the presence of IBMX was able to strongly stimulate
phosphorylation of residue 916 of both the Ras-GRF1(900-983) truncation mutant (not shown) and of full-length Ras-GRF1 (Fig. 6B) as indicated by the appearance of the ~6.5-kDa CNBr
fragment. The absence of this fragment from the reactions derived from
the S916A mutant confirms the original assignment of this fragment to
be due to phosphorylation at residue 916. These results also demonstrate that, just as in the in vitro reactions, serine
916 is apparently a substrate for both PKA and a distinct,
carbachol-stimulated kinase in the cell. Note also that there are
additional phosphorylation events that are stimulated by carbachol in
both the wild-type and S916A forms of Ras-GRF1. For example, there is a
clear increase in phosphorylation of a band that has a mobility just
below the 21-kDa marker in response to carbachol but not to
forskolin.
Phosphorylation at Serine 916 Is Not Sufficient to Activate
Ras-GRF1--
To test whether phosphorylation at serine 916 was
sufficient to activate Ras-GRF1, the stable line of NIH-3T3 cells
called 3T3/GRF.427, which constitutively expresses Ras-GRF1, was used (19). Treatment of these cells with lysophosphatidic acid stimulates an
increase in the activity of Ras-GRF1 (19). Forskolin was unable to
induce any detectable increase in the activity of the Ras-GRF1 in these
cells (Fig. 7). Similar results were
found for Ras-GRF1 that was transiently expressed in NIH-3T3/hm1
fibroblasts (not shown). In addition to activation by
G
The effect of in vitro phosphorylation of Ras-GRF1 at serine
916 on exchange activity was also examined. Thus Ras-GRF1 was immunoprecipitated from unstimulated 3T3/GRF.427 cells in the absence
of phosphatase inhibitors. The Ras-GRF1 was then incubated with
baseline and peak fractions from the Mono-Q separation in the presence
of ATP and okadaic acid. A GEF assay with recombinant Ras was then
performed. No change in the activity of Ras-GRF1 was induced under
conditions where serine 916 was phosphorylated in vitro
(data not shown).
This study identifies serine 916 of the Ras-GRF1 exchange factor
as a target for phosphorylation in vivo in COS-7 cells and NIH-3T3 fibroblasts in response to both the activation of co-expressed muscarinic receptors and the activation of PKA. Mutation of serine 916 to alanine prevents full activation of the exchange activity of
Ras-GRF1 toward Ras. Clearly, however, phosphorylation at serine 916 does not provide a complete explanation of the activation of Ras-GRF1
by G-protein-coupled receptors because it is not, by itself, sufficient
to replicate this activation. It is likely that there are additional
sites at which phosphorylation occurs in response to agonist
stimulation and these events are also required for activation. The
absence of these further phosphorylation events would explain the
absence of activation in response to forskolin, which may be only able
to induce phosphorylation at serine 916. Evidence that there are indeed
increases in phosphorylation in response to carbachol at sites that are
not so stimulated by forskolin is shown in Fig. 6. Whether
phosphorylation at serine 916 in response to a cAMP/PKA signal may
contribute to the overall regulation of Ras-GRF1 activity in the cell
is unknown, but it is possible that this could provide an additional
point of cross-talk between the cAMP and Ras signaling systems
(36).
Ras-GRF1 is expressed exclusively in the neurons of the postnatal
central nervous system in rodents (10), where, based on the phenotypes
of knockout mice that apparently lack expression of Ras-GRF1 (12, 13),
it plays a significant physiological role (37, 38). It is reasonable to
question, therefore, whether the results from the COS-7 and NIH-3T3
model systems reflect a mechanism that is relevant to physiological
events in neuronal signaling. We have previously shown that Ras-GRF1 in
neonatal rat brains is a phosphoprotein, the phosphorylation state of
which is increased in response to the muscarinic agonist carbachol, and
that carbachol increases the exchange activity toward Ras that is
present in lysates of rat brains (18). Whether serine 916 of Ras-GRF1
is also a site for phosphorylation in neurons remains, however, to be
determined. It should also be noted that Ras-GRF1 may be expressed more
widely in human tissues than in rodents (39).
The Ras-GRF2 exchange factor (40) is highly homologous to Ras-GRF1,
with much of the difference being short insertion sequences that are
present only in Ras-GRF1. These insertions produce the larger size of
140 kDa for Ras-GRF1 rather than 135 kDa for Ras-GRF2. Both Ras-GRF1
and Ras-GRF2 bind calmodulin through their ilimaquinone domains and can
couple ionomycin-induced increases in cytosolic calcium into increased
activation of mitogen-activated protein kinase (20, 40). It is
striking, therefore, that serine 916 of Ras-GRF1 occurs within one of
the insert regions and so has no homologous residue in Ras-GRF2. Serine
916 and the adjacent residues are, however, fully conserved between
Ras-GRF1 from rodents and humans (5, 6, 41). Because I have found that
phosphorylation of serine 916 plays a functional role in the activation
of Ras-GRF1 by muscarinic receptors, it will be interesting to test
whether Ras-GRF2 is regulated in a similar manner.
Serine 916 lies N-terminal to the CDC25 domain in Ras-GRF1 that has the
exchange factor activity for Ras (42) and is just C-terminal to PEST
sequences that confer sensitivity, at least in vitro, to
proteolysis (43). This region of Ras-GRF2 contains a cyclin destruction
box (40). Because phosphorylation may be a signal for protein turnover
(44), and because this region of Ras-GRF1 may be concerned with
regulation of protein stability, it is possible that phosphorylation of
serine 916 also plays a role in the termination of signaling through
induced down-regulation of Ras-GRF1.
Another distinction between Ras-GRF1 and Ras-GRF2 had been that
I2 and others (45, 46) had
not found any exchange activity toward GTPases of the Rho family in
Ras-GRF1, whereas Ras-GRF2 has clear exchange activity for Rac (47).
Recently, however, Kiyono et al. (48) have demonstrated that
Rac exchange factor activity can be induced in Ras-GRF1 by the
co-expression of G-protein An overall picture of the regulation of Ras-GRF1 is still, therefore,
incomplete. Indeed, many GEFs for Ras superfamily GTPases are subject
to complex regulation through phosphorylation (49, 50), allosteric
interactions (51, 52), and subcellular redistribution (21). GEFs may
also play a role in the selection of targets for their substrate
GTPases (53). In the case of Ras-GRF1 and its activation by ionomycin,
there is now evidence that it can participate in the activation of Raf,
the Ras effector, through a mechanism that may be independent of
further activation of Ras (46). It is likely that these complexities
reflect the underlying function of Ras-GRF1 and other GEFs to serve as
key integrators and controllers of signaling pathways with activities
beyond the simple control of GTP binding to their substrates.

subunits from heterotrimeric G-proteins. Increases in Ras-GRF1
activity toward Ras that are stimulated by receptors coupled to
G-proteins are associated with enhanced phosphorylation of Ras-GRF1 on
one or more serine residues. Co-expression of Ras-GRF1 with subtype 1 human muscarinic receptors in COS-7 cells allowed mapping of a
carbachol-stimulated phosphorylation site to a region composed of
residues 916-976. Site-directed mutagenesis replaced each of the
serine residues within this region with alanine and demonstrated that
serine 916 is a major site of in vivo phosphorylation of Ras-GRF1 in both COS-7 cells and NIH-3T3 fibroblasts. Serine 916 was a
substrate for protein kinase A both in vivo and in
vitro, suggesting a novel link between the cAMP and Ras signaling
systems. Carbachol-dependent phosphorylation of serine 916 occurred through a protein kinase A-independent pathway, however.
Full-length Ras-GRF1 that contains an alanine 916 mutation was only
partially activated by carbachol, suggesting that phosphorylation at
residue 916 is necessary for full activation. Phosphorylation of serine
916 in response to forskolin treatment did not, however, increase the activity of Ras-GRF1, indicating that it is not sufficient for activation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
C) fused with triple hemagglutinin-1 tags
at their N termini have been described previously (18). To construct
the C-terminal half (residues 632-1262, called
N) as a fusion with
the epitope-tags, polymerase chain reaction using the primer
TCGGATCCTGCAAAGTGCTTCAGATT introduced an in-frame BamHI
restriction site for subcloning into pKH3. To prepare GRF1(900-983),
polymerase chain reaction between an upstream primer with a
BamHI site, TAGGATCCGCGACTGCAGGAGCCAAT (which preserves the
PstI site), and a downstream primer with an EcoRI
site, TAAGAATTCAGGTCAGAAGGTCTGGGTCAT, was performed, and the product
was subcloned into pKH3 and pGEX-2T. All constructs were sequenced. A
diagram of the truncation mutants is given in Fig.
1.

View larger version (13K):
[in a new window]
Fig. 1.
A schematic view of the Ras-GRF1 constructs
used in this study. All of the constructs shown were inserted into
the pKH3 vector for expression in mammalian cells as fusion proteins
with N-terminal, triple hemagglutinin-1 tags (23). The GRF1(900-983)
piece (in both wild-type and alanine 916 forms) was also inserted into
pGEX-2T for expression in E. coli as a fusion protein with
GST.
PstpKH3). The BamHI/EcoRI fragment encoding Ras-GRF1(900-983) was ligated into
PstpKH3 and
then cut with PstI and BstEII for insertion of
mutated fragments. Site-directed mutagenesis was performed using the
two-step megaprimer protocol (24). In the first round, polymerase chain
reactions were performed between mutagenic upstream primers
(ATGAAGGCCCCGCAAACAAGGA for serine 907 to alanine,
TTTCGAAGGATGGCTTTGGCCA for serine 916 to alanine,
ACACAGGCTTTGCCTCTGACCA for serine 923 to alanine, CAGGCTTTTCCGCTGACCAGAGA for serine 924 to alanine, and
TTTCGAAGGATGACTTTGGCCA for serine 916 to threonine)
and a downstream primer (TGAGCGTATCGTCGGTATCAAAGT) for the region
957-965 of Ras-GRF1. The product of this first reaction (the
megaprimer) was then used as the downstream primer in a second
polymerase chain reaction with a new upstream primer (GTGGACAATAACCGCAGC) for the region 882-887 of Ras-GRF1. The final product was cut with PstI and BstEII for
insertion into the vector. All mutated constructs were then sequenced.
PstpKH3GRF1(900-983)916A was then digested with BamHI
and EcoRI to subclone into pGEX-2T.
PstpKH3, and the orientation was checked with an
XbaI/SstI digest. The
PstpKH3Ras-GRF1 plasmid was then digested with PstI (reserving the
PstI/PstI fragment produced) and then with
BstEII. The PstI/BstEII fragment
including the S916A mutation was then inserted. The resulting plasmid
was then again cut with PstI, and the missing
PstI/PstI fragment was reinserted to restore the
full coding sequence. The orientation of the insertion was checked with
an EcoRI digest and sequencing of the mutation.
20 °C for 30 min. After
30 min at maximum speed in a microcentrifuge at 4 °C, the acetone
was removed, and the pellet was dried. The sample was then dissolved in
100 µl of 70% (v/v) HCOOH that contained 50 mg/ml CNBr and incubated in the dark at room temperature for 90 min. The reaction was dried in a
Speed-Vac, dissolved in 100 µl of water, dried again, dissolved in 50 µl of water, and dried again. The sample was dissolved in Tricine gel
sample buffer (0.1 M Tris-Cl, pH 6.8, 24% (w/v) glycerol, 8% (w/v) SDS, 0.2 M dithiothreitol, 0.02% (w/v) Coomassie
Blue G-250) and then separated by SDS-PAGE using a Tricine cathode buffer (0.1 M Tris, 0.1 M Tricine, 0.1% (w/v)
SDS). The gel was then either dried for direct autoradiography or
transferred first to a polyvinylidene difluoride membrane to allow
subsequent excision of bands and phosphoamino acid analysis (19).
20 °C in 50%
(v/v) glycerol at protein concentrations of 4 mg/ml by Bradford assay.
Cell extracts from 100-mm dishes were prepared in 200 µl of lysis
buffer (5 mM KCl, 5 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 10 mM HEPES-NaOH, pH 7.4, 1% (v/v) Triton X-100, 25 µg/ml
aprotinin, 25 µg/ml leupeptin, 100 µM
phenylmethylsulfonyl fluoride, 1 µM okadaic acid, 1 µM microcystin-LR) and clarified at 4 °C for 10 min in
a microcentrifuge at maximum speed. Extracts for Mono-Q separation were
prepared without okadaic acid and with additional 0.5 mM
dithiothreitol, spun at 100,000 × g for 45 min, and
filtered at 0.45 µm prior to chromatography. Reactions were performed
at 30 °C by mixing 36 µl of extract or 25 µl of column fraction
with 5 µg of substrate and 1 µCi of [
-32P]ATP (New
England Nuclear) in a final volume of 48 µl. As appropriate, PKI
(Calbiochem) was included in the reaction at the indicated concentrations. Reactions were terminated by addition of 4× Laemmli sample buffer and boiling for 5 min prior to separation by SDS-PAGE. To
screen the fractions from the Mono-Q column, samples were terminated by
binding to nitrocellulose filters (27) with a portion retained for
SDS-PAGE to confirm that the radioactivity was incorporated into the
assumed substrate. Dried gels were subject to autoradiography and
quantification on a phosphorimager.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
C) and the
C-terminal half (residues 632-1262, called
N) showed that it is the
C-terminal half that provides this phosphorylated fragment. The
~6.5-kDa fragment was excised and subjected to phosphoamino acid
analysis, which revealed it to contain phosphoserine (Fig. 2B).

View larger version (44K):
[in a new window]
Fig. 2.
Cyanogen bromide digests of Ras-GRF1 reveal a
phosphopeptide that is stimulated by carbachol. A, the
Ras-GRF1 constructs shown were co-expressed with hm1 as indicated in
COS-7 cells. After labeling with 32Pi and
treatment with 100 µM carbachol for 5 min, the Ras-GRF1
proteins were immunoprecipitated and digested with CNBr. Results shown
are autoradiographs of dried gels, with molecular mass markers shown at
right. The arrow indicates a fragment that is
only seen in the presence of all of hm1, carbachol stimulation, and the
C-terminal half of Ras-GRF1. B, phosphoamino acid analysis
of the ~6.5-kDa fragment produced in full-length Ras-GRF1 in the
presence of both hm1 and carbachol. The position of the standards,
indicated at right, was determined by ninhydrin staining. An
autoradiograph is shown.

View larger version (41K):
[in a new window]
Fig. 3.
A truncation mutant of Ras-GRF1 is
phosphorylated at serine 916. The Ras-GRF1(900-983) constructs
were transfected into NIH-3T3/hm1 fibroblasts and then
immunoprecipitated after metabolic labeling with
32Pi and stimulation with carbachol. The
immunoprecipitates were separated by SDS-PAGE and transferred to
nitrocellulose for Western blotting with the 12CA5 monoclonal and
enhanced chemiluminescent detection (23), which confirmed equal
expression of the constructs (upper panels). The membrane
was treated with 1 mM EDTA and 0.05% (w/v)
NaN3 in Tris-buffered saline, pH 8.0, to terminate the
chemiluminescence, and then autoradiographs were prepared
(lower panels).

View larger version (27K):
[in a new window]
Fig. 4.
The S916A mutant of Ras-GRF1 is
only partially activated by muscarinic receptors. NIH-3T3/hm1
fibroblasts were transfected with constructs that express the
full-length Ras-GRF1 proteins shown, serum-starved overnight, and then
stimulated with 100 µM carbachol as indicated.
Immunoprecipitates were prepared and processed for the GEF activity
assay with recombinant Ras (18, 19) with data shown as mean ± S.E. of triplicates (A) and a representative immunoblot
(sc-224 from Santa-Cruz Biotechnology) to show the recovery of the
Ras-GRF1 that was assayed (B).
A recombinant protein encompassing residues 900-983 of Ras-GRF1
produced in Escherichia coli as a fusion with GST was
therefore used as an in vitro substrate in protein kinase
assays. Extracts of NIH-3T3/hm1 fibroblasts that had been stimulated
with either carbachol or isobutylmethyl xanthine (IBMX), an inhibitor
of cAMP phosphodiesterase and thus indirect activator of PKA (29), were competent at phosphorylation of serine 916 (Fig.
5A). Inclusion of PKI, a
selective inhibitor of PKA (30), in the kinase assay was able to
completely inhibit the activity present in extracts from
IBMX-stimulated cells but only partially inhibit that from carbachol-stimulated cells. This result suggests that carbachol induces
a kinase activity toward serine 916 that is distinct from PKA. Note
that hm1, although usually characterized as coupling through Gq
G-proteins to the activation of phospholipase C (31), have been
reported to activate PKA when expressed in fibroblasts (32).
Fractionation of the extract from carbachol-stimulated cells by Mono-Q
chromatography revealed two peaks of kinase activity toward serine 916 (Fig. 5B). However, both of these are inhibited by 200 nM PKI (the first peak is reduced by >95% and the second peak is reduced by >60%) and are thus likely to be two forms of PKA
(33). This result suggests that a different purification scheme will be
required to identify the carbachol-stimulated kinase.

View larger version (30K):
[in a new window]
Fig. 5.
In vitro phosphorylation of serine
916. A, lysates of NIH-3T3/hm1 fibroblasts that had
been pretreated with 100 µM carbachol for 5 min or with
50 µM IBMX for 30 min prior to lysis were incubated with
GST-GRF1(900-983) (wt) or with GST-GRF1(900-983)916A
(916A) and [
-32P]ATP. Protein kinase
inhibitor (5-24) (PKI) was included in the reaction as
shown. Samples were separated by SDS-PAGE, and an autoradiograph is
shown. Bands were also quantified using a phosphorimager. PKI at 200 nM inhibited 100% of the phosphorylation by
ionomycin-stimulated extracts and 79% of the phosphorylation by
carbachol-stimulated extracts. B, separation of the kinase
activity toward serine 916 by chromatography on a Mono-Q column.
Reactions were terminated by binding to nitrocellulose filters and
quantified in a scintillation counter. Control experiments using
GST-GRF1(900-983)916A as substrate (not shown) demonstrated that
serine 916 was required for the activity peaks shown.

View larger version (41K):
[in a new window]
Fig. 6.
In vivo phosphorylation of serine
916. A, experiments were performed as for Fig.
3A, with 50 µM Rp-cAMP-S for 30 min prior to
carbachol where indicated (+). B, COS-7 cells were
co-transfected with
PstpKH3Ras-GRF1 (wt) or
PstpKH3Ras-GRF1(S916A) (916A) plus pCDhM1 and pCDhM2
(18). After labeling with 32Pi, the cells were
treated with 100 µM carbachol for 5 min or with 100 µM IBMX for 30 min plus 20 µM forskolin for
5 min as indicated. Immunoprecipitation and digestion with CNBr was
performed as for Fig. 2A, and an autoradiograph is
shown.

-dependent phosphorylation, Ras-GRF1 is also able to
couple ionomycin-induced increases in cytosolic calcium to increases in
mitogen-activated protein kinase activity (20), although ionomycin does
not produce an increase in the activity of Ras-GRF1 measured in
vitro (20, 22, 35). The combination of ionomycin plus forskolin
was therefore tested to establish whether it might serve to stimulate
Ras-GRF1, but again, no increase in GEF activity toward Ras was found
(Fig. 7).

View larger version (24K):
[in a new window]
Fig. 7.
Forskolin does not increase the activity of
Ras-GRF1 measured in vitro. 3T3/GRF.427
fibroblasts were stimulated with 4.8 µM lysophosphatidic
acid (LPA) (
), with 100 µM IBMX for 30 min
plus 20 µM forskolin for 5 min (
), or with IBMX,
forskolin, and 1 mM ionomycin for 5 min (
). The Ras-GRF1
was then immunoprecipitated and assayed for exchange activity as
described (18, 19), except that GST-Ras was used as the substrate. Data
shown are mean ± S.E. from triplicate assays. Only
lysophosphatidic acid stimulated an increase in exchange activity above
control incubations (
).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

subunits. The DBL and plekstrin
homology domains that mediate Rac exchange factor activity (48) are
also required for the regulation of the Ras exchange activity of
Ras-GRF1 in response to ionomycin (45). This result suggests that
control of these two activities may be closely linked. Further, the
induction of Rac exchange activity by G
is also associated with
an increase in the phosphorylation state of Ras-GRF1, although in this
case the event is likely to be phosphotyrosine (48). We previously showed that G
induced an increase in the Ras exchange activity of
Ras-GRF1 (18), and this led to the identification of the serine 916 phosphorylation site in this study. In view of the close parallels
between the control of the Ras and Rac exchange activities of Ras-GRF1,
it is possible that phosphorylation at serine 916 may also participate
in the control of Rac exchange activity.
| |
ACKNOWLEDGEMENTS |
|---|
I thank Dr. D. L. Brautigan for the use of the Mono-Q chromatography system; Dr. D. Lowy for his original gift of the plasmid encoding CDC25Mm; Drs. P. B. Joel, C. E. Smith, and O. Tatsis for technical advice; Dr. A. Wolfman for his gift of recombinant c-Ha-Ras; and C. L. Smith for preparation of GST fusion proteins. I am indebted to Dr. I. G. Macara, in whose laboratory at the Markey Center for Cell Signaling of the University of Virginia these studies were initiated.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant CA-38888, American Cancer Society Grant IN-162, and a Research Starter Grant from the PhRMA Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
Wayne State University, 540 E. Canfield Ave., Detroit, MI 48201. Tel.:
313-577-6022; Fax: 313-577-6739; E-mail: r.mattingly@wayne.edu.
2 R. R. Mattingly, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GEF, guanine nucleotide exchange factor; hm1, subtype 1 human muscarinic receptors; PKA, cAMP-dependent protein kinase; PAGE, polyacrylamide gel electrophoresis; GST, glutathione S-transferase; IBMX, isobutylmethyl xanthine; PKI, protein kinase inhibitor; Tricine, N-[Tris-(hydroxymethyl)methyl]glycine.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Barbacid, M. (1987) Annu. Rev. Biochem. 56, 779-827[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Rosen, L. B., Ginty, D. D., Weber, M. J., and Greenberg, M. E. (1994) Neuron 12, 1207-1221[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Downward, J. (1998) Nature 396, 416-417[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Shou, C., Farnsworth, C. L., Neel, B. G., and Feig, L. A. (1992) Nature 358, 351-354[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Cen, H.,
Papageorge, A. G.,
Vass, W. C.,
Zhang, K.,
and Lowy, D. R.
(1993)
Mol. Cell. Biol.
13,
7718-7724 |
| 7. | Martegani, E., Vanoni, M., Zippel, R., Coccetti, P., Brambilla, R., Ferrari, C., Sturani, E., and Alberghina, L. (1992) EMBO J. 11, 2151-2157[Medline] [Order article via Infotrieve] |
| 8. | Wei, W., Schreiber, S. S., Baudry, M., Tocco, G., and Broek, D. (1993) Mol. Brain Res. 19, 339-344[Medline] [Order article via Infotrieve] |
| 9. | Ferrari, C., Zippel, R., Martegani, E., Gnesutta, N., Carrera, V., and Sturani, E. (1994) Exp. Cell Res. 210, 353-357[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Zippel, R., Gnesutta, N., Matus-Leibovitch, N., Mancinelli, E., Saya, D., Vogel, Z., and Sturani, E. (1997) Mol. Brain Res. 48, 140-144[Medline] [Order article via Infotrieve] |
| 11. | Sturani, E., Abbondio, A., Branduardi, P., Ferrari, C., Zippel, R., Martegani, E., Vanoni, M., and Denis-Donini, S. (1997) Exp. Cell Res. 235, 117-123[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Brambilla, R., Gnesutta, N., Minichiello, L., White, G., Roylance, A. J., Herron, C. E., Ramsey, M., Wolfer, D. P., Cestari, V., Rossi-Arnaud, C., Grant, S. G. N., Chapman, P. F., Lipp, H.-P., Sturani, E., and Klein, R. (1997) Nature 390, 281-286[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Itier, J.-M., Tremp, G. L., Leonard, J.-F., Multon, M.-C., Ret, G., Schweighoffer, F., Tocque, B., Bluet-Pajot, M.-T., Cormier, V., and Dautry, F. (1998) Nature 393, 125-126[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Buday, L.,
and Downward, J.
(1993)
Mol. Cell. Biol.
13,
1903-1910 |
| 15. | Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Shou, C., Wurmser, A., Ling, K., Barbacid, M., and Feig, L. A. (1995) Oncogene 10, 1887-1893[Medline] [Order article via Infotrieve] |
| 17. | Zippel, R., Orecchia, S., Sturani, E., and Martegani, E. (1996) Oncogene 12, 2697-2703[Medline] [Order article via Infotrieve] |
| 18. | Mattingly, R. R., and Macara, I. G. (1996) Nature 382, 268-272[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Mattingly, R. R., Saini, V., and Macara, I. G. (1999) Cell. Signal. 11, 603-610[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Farnsworth, C. L., Freshney, N. W., Rosen, L. B., Ghosh, A., Greenberg, M. E., and Feig, L. A. (1995) Nature 376, 524-527[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Buday, L., and Downward, J. (1993) Cell 73, 611-620[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Buchsbaum, R., Telliez, J.-B., Goonesekera, S., and Feig, L. A. (1996) Mol. Cell. Biol. 16, 4888-4896[Abstract] |
| 23. |
Mattingly, R. R.,
Sorisky, A.,
Brann, M. R.,
and Macara, I. G.
(1994)
Mol. Cell. Biol.
14,
7943-7952 |
| 24. | Barik, S. (1993) Methods Mol. Biol. 15, 277-286 |
| 25. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | McKiernan, C. J., Stabila, P. F., and Macara, I. G. (1996) Mol. Cell. Biol. 16, 4985-4995[Abstract] |
| 27. |
Wolfman, A.,
and Macara, I. G.
(1990)
Science
248,
67-69 |
| 28. | Pearson, R. B., and Kemp, B. E. (1991) Methods Enzymol. 200, 62-81[Medline] [Order article via Infotrieve] |
| 29. |
Schmidt, W.,
Poll-Jordan, G.,
and Loffler, G.
(1990)
J. Biol. Chem.
265,
15489-15495 |
| 30. |
Cheng, H. C.,
Kemp, B. E.,
Pearson, R. B.,
Smith, A. J.,
Misconi, L.,
Van Patten, S. M.,
and Walsh, D. A.
(1986)
J. Biol. Chem.
261,
989-992 |
| 31. |
Gutkind, J. S.,
Novotny, E. A.,
Brann, M. R.,
and Robbins, K. C.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4703-4707 |
| 32. |
Russell, M.,
Winitz, S.,
and Johnson, G. L.
(1994)
Mol. Cell. Biol.
14,
2343-2351 |
| 33. | Takahashi, N., Liapi, C., Anderson, W. B., and Breitman, T. R. (1991) Arch. Biochem. Biophys. 290, 293-302[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Connelly, P. A.,
Botelho, L. H.,
Sisk, R. B.,
and Garrison, J. C.
(1987)
J. Biol. Chem.
262,
4324-4332 |
| 35. | Mattingly, R. R. (1998) In Vitro Mol. Toxicol. 11, 57-62 |
| 36. | Bourne, H. R. (1995) Nature 376, 727-729[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Finkbeiner, S., and Dalva, M. B. (1998) BioEssays 20, 691-695[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Orban, P. C., Chapman, P. F., and Brambilla, R. (1999) Trends Neurosci. 22, 38-44[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Guerrero, C., Rojas, J. M., Chedid, M., Esteban, L. M., Zimonjic, D. B., Popescu, N. C., Font de Mora, J., and Santos, E. (1996) Oncogene 12, 1097-1107[Medline] [Order article via Infotrieve] |
| 40. | Fam, N. P., Fan, W. T., Wang, Z., Zhang, L. J., Chen, H., and Moran, M. F. (1997) Mol. Cell. Biol. 17, 1396-1406[Abstract] |
| 41. | Wei, W., Das, B., Park, W., and Broek, D. (1994) Gene 151, 279-284[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Coccetti, P., Mauri, I., Alberghina, L., Martegani, E., and Parmeggiani, A. (1995) Biochem. Biophys. Res. Comm. 206, 253-259[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Baouz, S.,
Jacquet, E.,
Bernardi, A.,
and Parmeggiani, A.
(1997)
J. Biol. Chem.
272,
6671-6676 |
| 44. |
Wulczyn, F. G.,
Krappmann, D.,
and Scheidereit, C.
(1998)
Nucleic Acids Res.
26,
1724-1730 |
| 45. | Freshney, N. W., Goonesekera, S. D., and Feig, L. A. (1997) FEBS Lett. 407, 111-115[CrossRef][Medline] [Order article via Infotrieve] |
| 46. |
Anborgh, P. H.,
Qian, X.,
Papageorge, A. G.,
Vass, W. C.,
DeClue, J. E.,
and Lowy, D. R.
(1999)
Mol. Cell. Biol.
19,
4611-4622 |
| 47. | Fan, W. T., Koch, C. A., deHoog, C. L., Fam, N. P., and Moran, M. F. (1998) Curr. Biol. 8, 935-938[CrossRef][Medline] [Order article via Infotrieve] |
| 48. |
Kiyono, M.,
Satoh, T.,
and Kaziro, Y.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4826-4831 |
| 49. |
Fleming, I. N.,
Elliott, C. M.,
Buchanan, F. G.,
Downes, C. P.,
and Exton, J. H.
(1999)
J. Biol. Chem.
274,
12753-12758 |
| 50. |
Ichiba, T.,
Hashimoto, Y.,
Nakaya, M.,
Kuraishi, Y.,
Tanaka, S.,
Kurata, T.,
Mochizuki, N.,
and Matsuda, M.
(1999)
J. Biol. Chem.
274,
14376-14381 |
| 51. |
Ebinu, J. O.,
Bottorff, D. A.,
Chan, E. Y. W.,
Stang, S. L.,
Dunn, R. J.,
and Stone, J. C.
(1998)
Science
280,
1082-1086 |
| 52. |
Hart, M. J.,
Jiang, X.,
Kozasa, T.,
Roscoe, W.,
Singer, W. D.,
Gilman, A. G.,
Sternweis, P. C.,
and Bollag, G.
(1998)
Science
280,
2112-2114 |
| 53. |
Giglione, C.,
and Parmeggiani, A.
(1998)
J. Biol. Chem.
273,
34737-34744 |
This article has been cited by other articles:
![]() |
H. Yang and R. R. Mattingly The Ras-GRF1 Exchange Factor Coordinates Activation of H-Ras and Rac1 to Control Neuronal Morphology Mol. Biol. Cell, May 1, 2006; 17(5): 2177 - 2189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Schmitt, E. S. Guire, T. Saneyoshi, and T. R. Soderling Calmodulin-Dependent Kinase Kinase/Calmodulin Kinase I Activity Gates Extracellular-Regulated Kinase-Dependent Long-Term Potentiation J. Neurosci., February 2, 2005; 25(5): 1281 - 1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yang, D. Cooley, J. E. Legakis, Q. Ge, R. Andrade, and R. R. Mattingly Phosphorylation of the Ras-GRF1 Exchange Factor at Ser916/898 Reveals Activation of Ras Signaling in the Cerebral Cortex J. Biol. Chem., April 4, 2003; 278(15): 13278 - 13285. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Mattingly, R. A. Gibbs, R. E. Menard, and J. J. Reiners Jr. Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 74 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. de Hoog, J. A. Koehler, M. D. Goldstein, P. Taylor, D. Figeys, and M. F. Moran Ras Binding Triggers Ubiquitination of the Ras Exchange Factor Ras-GRF2 Mol. Cell. Biol., March 15, 2001; 21(6): 2107 - 2117. [Abstract] [Full Text] |
||||
![]() |
M. Kiyono, J. Kato, T. Kataoka, Y. Kaziro, and T. Satoh Stimulation of Ras Guanine Nucleotide Exchange Activity of Ras-GRF1/CDC25Mm upon Tyrosine Phosphorylation by the Cdc42-regulated Kinase ACK1 J. Biol. Chem., September 15, 2000; 275(38): 29788 - 29793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baouz, E. Jacquet, K. Accorsi, C. Hountondji, M. Balestrini, R. Zippel, E. Sturani, and A. Parmeggiani Sites of Phosphorylation by Protein Kinase A in CDC25Mm/GRF1, a Guanine Nucleotide Exchange Factor for Ras J. Biol. Chem., January 12, 2001; 276(3): 1742 - 1749. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||